GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have ... among glucagon-like peptide-1 receptor agonists, ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

GLP-1 receptor agonists such as semaglutide and tirzepatide have proven to be highly effective in supporting weight loss by regulating appetite and metabolism. These medications work by mimicking ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

This post is in response to New Study Points to Using Ozempic to Treat Addiction By Suzette Glasner Ph.D. The treatment of Alcohol Use Disorder (AUD) has traditionally relied on behavioral ...